Mesoblast Limited

HQ Melbourne, Australia · New York · Singapore

Mission

Develop cell therapies for severe inflammatory diseases

Health & BiotechIndependently selected by SlideDoor

Products and services

  • RYONCIL
  • Rexlemestrocel-L
  • Mesenchymal lineage cells
  • Cell-therapy platform

Mesoblast develops and commercialises allogeneic cellular medicines for inflammatory conditions using proprietary mesenchymal lineage cells.

100–250 peopleFounded 2004

What stands out for senior leaders

We selected Mesoblast Limited for its focus on developing cell therapies for severe inflammatory diseases. In our judgement, that mission gives senior leaders a clear reason to examine the company: its product focus is directly connected to serious medical need.

Founded in 2004 and led by Dr Silviu Itescu, Mesoblast is publicly listed, with revenue of US$120.3M in FY2026. These facts give substance to the profile, although they do not, on their own, establish growth or clinical outcomes.

Its offices in Melbourne, New York and Singapore sit alongside a headcount band of 100–250. We see an international footprint within a relatively compact organisation, making it worth exploring for leaders interested in the intersection of biotechnology, strategy and public-market accountability.

Leadership areas

  • Operations & Strategy
  • Finance & Capital
  • Legal, Risk & Governance

The honest trade-off

Mesoblast may not suit leaders who prefer a privately held company rather than a publicly listed business. Its specialised focus on cell therapies may also be less aligned with those seeking a broader product remit outside health and biotechnology.

Questions leaders ask about Mesoblast Limited

What does Mesoblast Limited focus on?
Mesoblast operates in health and biotechnology, with a mission to develop cell therapies for severe inflammatory diseases.
Who leads Mesoblast Limited?
Mesoblast's CEO is Dr Silviu Itescu. The company was founded in 2004.
Where does Mesoblast have offices, and what is its scale?
Mesoblast has offices in Melbourne, New York and Singapore, with a headcount band of 100–250. It is publicly listed and recorded revenue of US$120.3M in FY2026.

Sources

Last checked November 2026

Headquarters
Melbourne, Australia
CEO
Dr Silviu Itescu
Founded
2004
People
100–250
Stage
Publicly listed
Market cap
A$2.64B (6 November 2026)
Revenue
US$120.3M (FY2026)
Offices
Melbourne, New York, Singapore

Checked against a public source

Website

More companies in Melbourne